Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
Oak Ridge, TN, April 01, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American College of Cardiology (ACC.24) at the Georgia World Congress Center in Atlanta, GA, April 6 – 8, 2024.
田納西州橡樹嶺，2024 年 4 月 1 日（GLOBE NEWSWIRE）— 達克索公司 （納斯達克股票代碼：DXR），血容量測量技術的全球領導者，今天宣佈將於2024年4月6日至8日在喬治亞州亞特蘭大喬治亞世界會議中心舉行的美國心臟病學會（ACC.24）上展出。
"ACC.24 is considered the premier cardiology exposition in the Americas, offering a prime opportunity for Daxor to broaden its reach within the entire cardiovascular community," said Michael Feldschuh, Daxor's CEO and President. "This conference presents an ideal platform for engaging with healthcare providers for whom effective volume management poses a significant challenge. Our blood volume analysis (BVA) technology provides 98% accurate, actionable data to optimize treatment plans and personalize care, improving outcomes while reducing duration and cost of care."
達克索首席執行官兼總裁邁克爾·費爾德舒說：“ACC.24被認爲是美洲首屈一指的心臟病學博覽會，爲達克索擴大其在整個心血管界的影響力提供了絕佳的機會。”“本次會議爲與醫療保健提供者互動提供了理想的平台，對他們來說，有效的音量管理構成了重大挑戰。我們的血容量分析（BVA）技術提供98％的準確性、可操作的數據，以優化治療計劃和個性化護理，改善預後，同時縮短護理時間和成本。”
The Company will be exhibiting at Booth #2312.
該公司將在 #2312 號展位展出。
Register for the event HERE.
註冊參加活動 這裏。
About American College of Cardiology
美國心臟病學會簡介
The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards, and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at .
美國心臟病學會（ACC）是改變心血管護理和改善所有人心臟健康的全球領導者。自1949年以來，作爲整個心血管護理團隊專業醫學教育的絕佳來源，ACC對140多個國家的心血管專業人員進行資格認證，這些專業人員符合嚴格資格並在健康政策、標準和指導方針的制定方面處於領先地位。通過其享譽全球的JACC期刊系列、NCDR註冊機構、ACC認證服務、全球成員部門網絡、CardioSmart患者資源等，該學院致力於確保一個科學、知識和創新優化患者護理和療效的世界。要了解更多，請訪問 。
About Daxor Corporation
關於達克索公司
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology HERE.
達克索公司（納斯達克股票代碼：DXR）是血容量測量技術的全球領導者，專注於血容量測試創新。我們開發並銷售 BVA-100 （血容量分析儀），美國食品藥品管理局批准的唯一一項診斷性血液檢測，可與患者特定的標準相比，提供安全、準確、客觀的血容量狀態和成分定量。美國領先的醫院中心已經進行了超過65,000次檢測，提高了各種手術和醫療條件下的醫院績效指標，包括顯著降低心力衰竭和重症監護的死亡率和再入院率。在美國國立衛生研究院的支持下，達克索正在心力衰竭治療領域進行多項試驗，並與美國國防部簽訂了開發分析儀的合同，以改善戰鬥傷亡護理。Daxor的使命是通過血容量分析實現最佳的液體管理，從而推動醫療保健的發展。達克索的視野是所有人的最佳血容量。欲了解更多信息，請訪問我們的網站 daxor.com。註冊接收有關 Daxor 創新技術的新聞 這裏。
Forward-Looking Statements
前瞻性陳述
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
本新聞稿中的某些陳述可能包括1995年《私人證券訴訟改革法》所指的前瞻性陳述，包括但不限於有關僱用銷售人員和擴大分銷渠道的影響的陳述。前瞻性陳述是基於當前預期和假設的關於未來事件的預測、預測和其他陳述，因此受到風險和不確定性的影響。許多因素可能導致未來的實際事件與本新聞稿中的前瞻性陳述存在重大差異，包括但不限於與我們的上市後臨床數據收集活動相關的風險、我們的產品對患者的益處、我們對產品開發和商業化工作的期望、我們提高市場和醫生對我們產品的接受度的能力、潛在的競爭產品供應、知識產權保護、美國食品藥品管理局監管行動、我們整合收購的能力企業、我們對與被收購企業的預期協同效應和收益的預期，以及我們在向美國證券交易委員會提交的文件中描述的其他風險和不確定性。前瞻性陳述僅代表截至發表之日。達克索不承擔任何公開更新或修改任何前瞻性陳述的義務，無論是由於新信息、未來事件還是其他原因。
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
brets@coreir.com
投資者關係聯繫人：
佈雷特·夏皮羅
CORE IR 高級管理合夥人
516-222-2560
brets@coreir.com
譯文內容由第三人軟體翻譯。